SCHEMBL4863765

SCHEMBL4863765

Cc1ccc2c(c1)N(C(=O)Nc1ccccc1)CCCC2

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.62
TP53 P04637 4/20 0.60
NPC1 O15118 3/20 0.60
RAB9A P51151 3/20 0.60
NFKB1 P19838 2/20 0.60
NFKB2 Q00653 2/20 0.60
RELA Q04206 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
PKM P14618 1/20 0.58
LMNA P02545 3/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
MAPT P10636 1/20 0.55
ALDH1A1 P00352 1/20 0.55
MAPK1 P28482 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870805 0.90 HTR2A (0.63) POLBTP53NPC1RAB9ANFKB1
SCHEMBL4863201 0.89 POLB (0.58) POLBTP53NPC1RAB9ANFKB1
SCHEMBL4870796 0.86 TP53 (0.59) POLBTP53NPC1RAB9ANFKB1
SCHEMBL4863733 0.85 TP53 (0.58) POLBTP53NPC1RAB9ANFKB1
SCHEMBL4862919 0.85 TP53 (0.58) POLBTP53NPC1RAB9ANFKB1
SCHEMBL4863126 0.85 POLB (0.83) POLBTP53NPC1RAB9ANFKB1
SCHEMBL4867471 0.84 TP53 (0.81) POLBTP53NPC1RAB9ANFKB1
SCHEMBL14089574 0.84 LMNA (0.71) POLBTP53NPC1RAB9ANFKB1
SCHEMBL4869023 0.83 TP53 (0.78) POLBTP53NPC1RAB9ANFKB1
SCHEMBL4870812 0.81 ATM (0.69) POLBTP53NPC1RAB9ANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US claimed
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 POLB 2390/4885TP53 4170/4885NPC1 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.